What he’d much rather talk about is Yosemite, the oncology-focused venture firm he launched in 2023 to, in part, build biotech companies from scratch, out of early academic research, using a mix of no-strings-attached philanthropy and old-fashioned venture capital. Three years in, Jobs is ambitious about turning Yosemi...
Key Takeaways
- Jobs is ambitious about turning Yosemite into a serious player
- Among the portfolio companies he’s proudest of are Azalea
- Cluster of blockbuster drugs are all losing patent protection in roughly the same window